Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Isentress / Isentress HD (raltegravir by Year
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. sales ($M) ($M)
Merck Isentress / Isentress HD (raltegravir: $181M in FY2025, down 2.2% from a year earlier. That is the lowest of the 10 years on record here.
Where the FY2025 figure comes from
“|| Isentress/Isentress HD | 325 | 394 | -18 | 181 | 185 | -3 | 144 | 209 | -31”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 181 | -2.2% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 185 | -14.0% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 215 | -21.5% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 274 | -6.8% | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 294 | -9.8% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 326 | -18.1% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 398 | -22.4% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 513 | -9.2% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 565 | -21.6% | Form 10-K (filed 2020-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 721 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up isentress / Isentress HD (raltegravir
Cite this data
StockData. (2026). Merck Isentress / Isentress HD (raltegravir ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-isentress-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.